Cadila Of India, WHO To Collaborate On Rabies Treatment
This article was originally published in PharmAsia News
Executive Summary
India's Cadila Healthcare said its Zydus Cadila arm and the World Health Organization have agreed to collaborate on a possible treatment for rabies. In a stock exchange filing, Cadila said the aim of the agreement is to develop a drug cocktail based on monoclonal antibodies to treat the disease that results from a bite by a rabid animal. WHO is to provide antibodies with the potential of neutralizing the rabies virus, along with the genetic sequences of the virus. Cadila's Zydus Research Center is to evaluate the possibility of that information leading to an adjuvant therapy. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.